704 related articles for article (PubMed ID: 17389658)
1. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly.
Braun J; McHugh N; Singh A; Wajdula JS; Sato R
Rheumatology (Oxford); 2007 Jun; 46(6):999-1004. PubMed ID: 17389658
[TBL] [Abstract][Full Text] [Related]
2. Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis.
Reich K; Segaert S; Van de Kerkhof P; Durian C; Boussuge MP; Paolozzi L; Wajdula J; Boggs R
Dermatology; 2009; 219(3):239-49. PubMed ID: 19752505
[TBL] [Abstract][Full Text] [Related]
3. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis.
Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Grassnickel L; Rudwaleit M; Sieper J; Braun J
Arthritis Rheum; 2003 Jun; 48(6):1667-75. PubMed ID: 12794835
[TBL] [Abstract][Full Text] [Related]
4. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis.
van der Heijde D; Da Silva JC; Dougados M; Geher P; van der Horst-Bruinsma I; Juanola X; Olivieri I; Raeman F; Settas L; Sieper J; Szechinski J; Walker D; Boussuge MP; Wajdula JS; Paolozzi L; Fatenejad S;
Ann Rheum Dis; 2006 Dec; 65(12):1572-7. PubMed ID: 16968715
[TBL] [Abstract][Full Text] [Related]
5. Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept.
Boonen A; Patel V; Traina S; Chiou CF; Maetzel A; Tsuji W
J Rheumatol; 2008 Apr; 35(4):662-7. PubMed ID: 18278836
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial.
Davis JC; Van Der Heijde D; Braun J; Dougados M; Cush J; Clegg DO; Kivitz A; Fleischmann R; Inman R; Tsuji W;
Arthritis Rheum; 2003 Nov; 48(11):3230-6. PubMed ID: 14613288
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
[TBL] [Abstract][Full Text] [Related]
8. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
Gniadecki R; Robertson D; Molta CT; Freundlich B; Pedersen R; Li W; Boggs R; Zbrozek AS
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis.
Mease PJ; Woolley JM; Singh A; Tsuji W; Dunn M; Chiou CF
J Rheumatol; 2010 Jun; 37(6):1221-7. PubMed ID: 20395648
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Brandt J; Listing J; Haibel H; Sörensen H; Schwebig A; Rudwaleit M; Sieper J; Braun J
Rheumatology (Oxford); 2005 Mar; 44(3):342-8. PubMed ID: 15561737
[TBL] [Abstract][Full Text] [Related]
11. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
[TBL] [Abstract][Full Text] [Related]
12. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha.
Gorman JD; Sack KE; Davis JC
N Engl J Med; 2002 May; 346(18):1349-56. PubMed ID: 11986408
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial.
Krueger GG; Langley RG; Finlay AY; Griffiths CE; Woolley JM; Lalla D; Jahreis A
Br J Dermatol; 2005 Dec; 153(6):1192-9. PubMed ID: 16307657
[TBL] [Abstract][Full Text] [Related]
14. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
Davis JC; Van der Heijde DM; Dougados M; Braun J; Cush JJ; Clegg DO; Inman RD; de Vries T; Tsuji WH
J Rheumatol; 2005 Sep; 32(9):1751-4. PubMed ID: 16142873
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Calin A; Dijkmans BA; Emery P; Hakala M; Kalden J; Leirisalo-Repo M; Mola EM; Salvarani C; Sanmartí R; Sany J; Sibilia J; Sieper J; van der Linden S; Veys E; Appel AM; Fatenejad S
Ann Rheum Dis; 2004 Dec; 63(12):1594-600. PubMed ID: 15345498
[TBL] [Abstract][Full Text] [Related]
16. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54 weeks: the CRYSTEL study.
Daudén E; Griffiths CE; Ortonne JP; Kragballe K; Molta CT; Robertson D; Pedersen R; Estojak J; Boggs R
J Eur Acad Dermatol Venereol; 2009 Dec; 23(12):1374-82. PubMed ID: 19563497
[TBL] [Abstract][Full Text] [Related]
17. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy.
Davis JC; van der Heijde D; Dougados M; Woolley JM
Arthritis Rheum; 2005 Aug; 53(4):494-501. PubMed ID: 16082640
[TBL] [Abstract][Full Text] [Related]
18. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks.
Davis JC; van der Heijde DM; Braun J; Dougados M; Cush J; Clegg D; Inman RD; Kivitz A; Zhou L; Solinger A; Tsuji W
Ann Rheum Dis; 2005 Nov; 64(11):1557-62. PubMed ID: 15843448
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
20. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial.
van der Heijde D; Klareskog L; Singh A; Tornero J; Melo-Gomes J; Codreanu C; Pedersen R; Freundlich B; Fatenejad S
Ann Rheum Dis; 2006 Mar; 65(3):328-34. PubMed ID: 16079172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
